PubMed Health⌕ Search

PubMed · 12357462

A sample injection device for flow cytometers.

Abstract

BACKGROUND: The sample injection systems of flow cytometers employ either a pressure differential between the sample vial and the sheath fluid reservoir or volumetric injection of the sample from a syringe. The pressure differential method facilitates rapid and efficient flushing to eliminate carryover between samples, but does not allow accurate determination of the rate of sample flow and cell concentration. Volumetric injection, which comprises a valve for switching the sample flow, facilitates highly accurate measurement of the cell concentration, but requires a less efficient and more time-consuming flushing procedure. METHODS: Applying a removable syringe, which connects to the inlet of the sample tubing via a tight sealing, we eliminate the valve and obtain efficient flushing while maintaining the advantage of volumetric sample injection. RESULTS: This device gives highly constant sample flow rates strictly proportional to syringe velocity over the range 0.2-50 microl/min with a settling time of about 2 sec. CONCLUSION: This device has the same precision as the conventional sample injection system, whereas the speed and efficiency of flushing are improved greatly.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Harald B Steen. 2002-10-01. A sample injection device for flow cytometers.. https://doi.org/10.1002/cyto.10147

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Interphase and monoastral-mitotic phenotypes of overexpressed MAP4 are modulated by free tubulin concentrations.

The microtubule-associated protein 4 (MAP4) has recently been shown to counteract destabilization of interphase microtubules caused by catastrophe promotion but not by tubulin sequestering. To address how MAP4 discriminates between destabilization of microtubules by these two mechanisms, we have evaluated the combined phenotypes of MAP4 coexpressed with Op18/stathmin family member derivatives with either catastrophe-promoting or sequestering activities. This approach relies on the finding that overexpression of MAP4 alone stabilizes microtubules during all phases of the cell cycle in human leukemia cells, and causes a potent mitotic block and a dramatic, previously unobserved, phenotype characterized by large monoastral spindles. Coexpression of either catastrophe-promoting or tubulin-sequestration-specific Op18 derivatives was found to modulate the activity of ectopic MAP4 during mitosis, but with differential functional outcome. Interestingly, the tubulin-sequestering derivative suppressed the monoastral mitotic phenotype of MAP4 (i.e. coexpression facilitated the formation of functional spindles). To evaluate whether this phenotypic suppression could be explained by tubulin-sequestration-dependent modulation of MAP4 activity, a plasma-membrane-targeted, tubulin-sequestering chimera was constructed to decrease the cytosolic free tubulin concentration substantially. This chimera likewise suppressed the monoastral phenotype caused by overexpression of MAP4, suggesting a direct downregulation of MAP4 activity by reduced free tubulin concentrations.

Flow Cytometry↗

Real-time quantitation of HIV-1 p24 and SIV p27 using fluorescence-linked antigen quantification assays.

We developed fluorescence-linked antigen quantification (FLAQ) assays for HIV-1 and SIV antigen quantitation. The assays utilize polystyrene microspheres coated with monoclonal antibodies against HIV-1 Gag p24 or SIV Gag p27, which are incubated with unknown samples, flourochrome-conjugated detector antibody, and lysing agent. The fluorescence of individual microspheres is measured using flow cytometry. The speed, simplicity, and wide dynamic range of FIAQ assays makes them superior to enzyme-linked immunosorbent assays for many applications performed in research laboratories.

Flow Cytometry↗

Intravenous immunoglobulin-induced panel reactive antibody A reduction: not all preparations are created equal.

BACKGROUND: Use of intravenous (IV) immunoglobulin (Ig) to obtain panel reactive antibody (PRA) A reduction in sensitized patients has been widely reported. Because no IVIg preparation is formulated specifically for this purpose, the authors have sought to determine whether, through laboratory testing, they could guide the rational choice of product for clinical use. METHODS: Using a flow cytometric approach, the authors have quantitatively determined the capacity of 22 different IVIg preparations to cause PRA reduction. RESULTS: IVIg preparations showed considerable variability in their individual capacity to reduce serum PRA. Protein-A pretreatment of IVIg preparations was found to reduce their capacity to cause PRA reduction. CONCLUSION: Laboratory screening of IVIg preparations provides a rational basis for the selection of product for administration to patients in whom the aim is to produce a PRA reduction. Experiments involving protein-A treatment of IVIg preparations indicate that immunoglobulin G is the principal factor involved in the abrogation of serum reactivity.

Flow Cytometry↗